- Home
- NEGG vs CDXS Comparison
NEGG vs CDXS Comparison
Compare NEGG & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEGG | CDXS |
|---|---|---|
| Founded | 2001 | 2002 |
| Country | United States | United States |
| Employees | 714 | N/A |
| Industry | Other Specialty Stores | Major Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.3M | 256.3M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | NEGG | CDXS |
|---|---|---|
| Price | $13.37 | $1.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.3K | ★ 752.4K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | N/A | $14.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $12.50 | $0.96 |
| 52 Week High | $96.29 | $2.98 |
Technical Indicators
Market Signals| Indicator | NEGG | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 37.65 | 37.72 |
| Support Level | $12.52 | $1.22 |
| Resistance Level | $20.11 | $1.76 |
| Average True Range (ATR) | 0.96 | 0.09 |
| MACD | -0.25 | -0.00 |
| Stochastic Oscillator | 17.84 | 22.35 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products, and provides certain third-party logistics services globally. Geographically, it operates in the United States, Canada, and the Rest of the world.
About CDXS Codexis Inc.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.